: Eli Lilly’s tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in late-stage trial

Eli Lilly & Co. LLY said Thursday its tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in a late-stage trial. Participants in the phase 3 trial called Surmount-2 lost up to 34.4 pounds, the company said in a statement. The company expects to complete its submission for the drug in the coming weeks and expects regulatory action by as early as late 2023. The trial involved 938 adults and was the second phase 3 trial to evaluate the drug as a treatment for chronic weight management. “The degree of mean weight reduction seen in SURMOUNT-2 has not been previously achieved in phase 3 trials for obesity or overweight and type 2 diabetes,” said Dr. Jeff Emmick, senior vice president for product development. The company will continue to review the data and will present them at the American Diabetes Association’s 83rd Scientific Sessions and submit them to a peer-reviewed journal. The stock was up 1.2% premarket.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.